Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1540-8159.2007.00944.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Heterogeneity in American and European Peripheral Artery Disease Guidelines on Non-statin Lipid-Lowering Therapy and Rivaroxaban.
Thromb Haemost
January 2025
Yale University Center for Outcomes Research and Evaluation, Boston, United States.
No abstract for this Commentary/Viewpoint. Glad to add if the Editorial Office sees necessary.
View Article and Find Full Text PDFOvercoming Resistance to FLT3-ITD Therapeutics.
J Med Chem
December 2024
Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, 715 Sumter Street, Columbia, South Carolina 29208, United States.
FLT3-ITD (internal tandem duplication) is a key driver of acute myeloid leukemia (AML), and several FDA-approved drugs target this mutant kinase. This Viewpoint describes the discovery of inhibitors targeting point mutants and the development of SILA123, a highly potent and selective type II FLT3 inhibitor. In studies, SILA-123 significantly suppressed tumor growth in allograft models, demonstrating its potential in treating resistant AML.
View Article and Find Full Text PDFWhat to Expect From a Low-Nicotine Product Standard for Cigarettes: A Response to "Denicotinized" Tobacco.
JAMA
December 2024
Department of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Lessons Learned From E-Cigarettes Should Affect FDA Regulation of Nicotine Pouches.
JAMA
December 2024
Rutgers Institute for Nicotine & Tobacco Studies, New Brunswick, New Jersey.
Article Synopsis
Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes.
JAMA Ophthalmol
January 2025
Department of Medicine, Division of Pharmacoepidemiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Article Synopsis
- Empagliflozin may reduce the risk of diabetic retinopathy (DR) by preventing the loss of retinal pericytes, but its effectiveness compared to DPP4 inhibitors in patients with type 2 diabetes (T2D) is not well established.
- A study was conducted using U.S. insurance claims data from 2014 to 2019, focusing on adults with T2D who were newly prescribed either empagliflozin or a DPP4 inhibitor, and looking at the incidence of nonproliferative DR and its progression.
- Results showed that among matched patient pairs, empagliflozin's impact on the rates of incident DR and progression was analyzed, with significant data collected over an average
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!